"Dutasteride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.
| Descriptor ID |
D000068538
|
| MeSH Number(s) |
D04.210.500.925.100.125
|
| Concept/Terms |
Dutasteride- Dutasteride
- 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
|
Below are MeSH descriptors whose meaning is more general than "Dutasteride".
Below are MeSH descriptors whose meaning is more specific than "Dutasteride".
This graph shows the total number of publications written about "Dutasteride" by people in this website by year, and whether "Dutasteride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dutasteride" by people in Profiles.
-
Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. Asian J Androl. 2016 Jul-Aug; 18(4):520-4.
-
5a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013 Jul; 154(7):2296-307.
-
Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5a-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol. 2012 Sep; 188(3):757-61.
-
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85.
-
Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010 May; 75(5):1144-8.
-
Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.